Comparisons of sulfonylureas with thiazolidinediones, and of DPP-4 inhibitors with thiazolidinediones (Table 2; eFigures 2 and 3 in the Supplement) show no difference in reaching HbA1c levels of 7% of total hemoglobin or less, or in hazard of myocardial infarction, kidney disorders, and eye disorders in patients with T2D after recalibration of P values as well as after the meta-analysis. This evidence concerns the gene DPP4 and eye disorder.